{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:33:20Z","timestamp":1714782800052},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"DOI":"10.7759\/cureus.59604","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T21:19:50Z","timestamp":1714771190000},"source":"Crossref","is-referenced-by-count":0,"title":["Amitriptyline-Induced Hyperprolactinemia in a Pediatric Patient"],"prefix":"10.7759","author":[{"given":"Safia","family":"Centner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Gurnurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirin","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Hyperprolactinemia","author":"Thapa S","year":"2023","unstructured":"Thapa S, Bhusal K. Hyperprolactinemia. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref2","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre DL","year":"2007","unstructured":"Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007, 3:929-51.","journal-title":"Ther Clin Risk Manag"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2165\/11533140-000000000-00000","article-title":"Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management","volume":"24","author":"Coker F","year":"2010","unstructured":"Coker F, Taylor D. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. CNS Drugs. 2010, 24:563-74. 10.2165\/11533140-000000000-00000","journal-title":"CNS Drugs"},{"key":"ref4","article-title":"Risperidone","author":"McNeil SE","year":"2023","unstructured":"McNeil SE, Gibbons JR, Cogburn M. Risperidone. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.874705","article-title":"Risperidone induced hyperprolactinemia: from basic to clinic studies","volume":"13","author":"Stojkovic M","year":"2022","unstructured":"Stojkovic M, Radmanovic B, Jovanovic M, Janjic V, Muric N, Ristic DI. Risperidone induced hyperprolactinemia: from basic to clinic studies. Front Psychiatry. 2022, 13:874705. 10.3389\/fpsyt.2022.874705","journal-title":"Front Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790150049008","article-title":"Serotonin function and mechanism of action of antidepressant treatment. Effects of amitriptyline and desipramine","volume":"41","author":"Charney DS","year":"1984","unstructured":"Charney DS, Heninger GR, Sternberg DE. Serotonin function and mechanism of action of antidepressant treatment. Effects of amitriptyline and desipramine. Arch Gen Psychiatry. 1984, 41:359-65. 10.1001\/archpsyc.1984.01790150049008","journal-title":"Arch Gen Psychiatry"},{"key":"ref7","article-title":"Amitriptyline","author":"Thour A","year":"2023","unstructured":"Thour A, Marwaha R. Amitriptyline. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5214\/ans.0972.7531.12190210","article-title":"Serotonin and CGRP in migraine","volume":"19","author":"Aggarwal M","year":"2012","unstructured":"Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012, 19:88-94. 10.5214\/ans.0972.7531.12190210","journal-title":"Ann Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1308483","article-title":"Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline","volume":"18","author":"Hellings JA","year":"2017","unstructured":"Hellings JA, Arnold LE, Han JC. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline. Expert Opin Pharmacother. 2017, 18:581-8. 10.1080\/14656566.2017.1308483","journal-title":"Expert Opin Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1977.tb03334.x","article-title":"Neuroendocrine control of prolactin in experimental animals","volume":"6 Suppl","author":"Meites J","year":"1977","unstructured":"Meites J. Neuroendocrine control of prolactin in experimental animals. Clin Endocrinol (Oxf). 1977, 6 Suppl:9S-18S. 10.1111\/j.1365-2265.1977.tb03334.x","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/250935-amitriptyline-induced-hyperprolactinemia-in-a-pediatric-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T21:19:54Z","timestamp":1714771194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/250935-amitriptyline-induced-hyperprolactinemia-in-a-pediatric-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.59604","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,3]]}}}